- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device - intubated patients.

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin, pravastatin or atorvastatin ≤40 mg/d or rosuvastatin ≤20 mg/d - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device - intubated patients.

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin or atorvastatin. for the latter 2 statins, patients taking doses >40 mg/d will be excluded - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device

- known pregnancy or breastfeeding - estimated glomerular filtration rate (egfr) <30 ml/min/1.73m2 or undergoing dialysis (ckd stages 4-5). - history of active liver disease, cholelithiasis, hypothyroidism, or rhabdomyolysis (suspected or confirmed). - known hypersensitivity to fenofibrate or fenofibric acid. - ongoing treatment with fenofibrate, clofibrate, warfarin and other coumarin anticoagulants, glimepiride, cyclosporine, tacrolimus - use of statins other than simvastatin or atorvastatin. for the latter 2 statins, patients taking doses >40 mg/d will be excluded - prisoners/incarcerated individuals - inability to read, write or no access to a smart phone, computer or tablet device